Free Trial

Vistagen Therapeutics (VTGN) Insider Trading & Ownership

Vistagen Therapeutics logo
$2.58 +0.05 (+1.98%)
(As of 11/22/2024 ET)

Vistagen Therapeutics (NASDAQ:VTGN) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
1.29%
Number Of
Insiders Buying
(Last 3 Years)
4
Amount Of
Insider Buying
(Last 3 Years)
$18.13 M
Number Of
Insiders Selling
(Last 3 Years)
1
Amount Of
Insider Selling
(Last 3 Years)
$53,400.00
Get VTGN Insider Trade Alerts

Want to know when executives and insiders are buying or selling Vistagen Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

VTGN Insider Buying and Selling by Quarter

Vistagen Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/7/2023Commodore Capital LpMajor ShareholderBuy775,756$23.15$17,958,751.40  
8/18/2022Jerry B GinDirectorBuy3,333$5.40$17,998.20  
8/17/2022Reid G AdlerInsiderBuy10,000$5.10$51,000.00  
8/17/2022Shawn SinghCEOBuy20,000$5.10$102,000.00  
7/12/2022Venrock Healthcare Capital ParMajor ShareholderSell2,000$26.70$53,400.00  
(Data available from 1/1/2013 forward)

VTGN Insider Trading Activity - Frequently Asked Questions

The list of insiders at Vistagen Therapeutics includes Commodore Capital Lp, Jerry B Gin, Reid G Adler, Shawn Singh, and Venrock Healthcare Capital Par. Learn more on insiders at VTGN.

1.29% of Vistagen Therapeutics stock is owned by insiders. Learn more on VTGN's insider holdings.

The following insider purchased VTGN shares in the last 24 months: Commodore Capital Lp ($17,958,751.40).

Insiders have purchased a total of 775,756 VTGN shares in the last 24 months for a total of $17,958,751.40 bought.

Vistagen Therapeutics Key Executives

  • Mr. Shawn K. Singh J.D. (Age 61)
    CEO & Director
    Compensation: $947.92k
  • Ms. Cynthia Lynn Anderson CPA (Age 55)
    Chief Financial Officer
    Compensation: $391.2k
  • Mr. Joshua S. Prince M.B.A. (Age 53)
    Chief Operating Officer
    Compensation: $568.44k
  • Mr. Reid G. Adler Esq. (Age 69)
    J.D., Chief Corporate Development Officer & General Counsel
    Compensation: $675k
  • Mr. Mark Adrian McPartland (Age 58)
    Senior Vice President of Investor Relations
    Compensation: $300k
  • Ms. Trisha Fitzmaurice
    Senior Vice President of Human Resources
  • Dr. Allen Easley Cato III
    M.D., Ph.D., Senior Vice President of Development Operations
  • Dr. Mark J. Ginski Ph.D. (Age 52)
    Senior VP and Head of Chemistry, Manufacturing & Controls
  • Mr. Mark Flather
    Senior Vice President of Corporate Strategy & Capital Markets
  • Dr. Erik Berglund M.D.
    Ph.D., Senior VP of Global Regulatory Affairs & Pharmacovigilance


This page (NASDAQ:VTGN) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners